A wealth of data indicates that certain genetic abnormalities can target specific cytotoxic drugs and intervene at an early step as a mechanism of resistance in the treatment of non-small-cell lung cancer. Therefore prescribing
E. Felip, MD
Advertisement
Articles by E. Felip, MD
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on CancerNetwork
1
INTerpath-001 Data Detail Survival, Subgroup, and Safety Findings in Melanoma
2
Top Poster Takeaways for Prostate Cancer From 2026 ESMO Congress
3
Tarlatamab Maintenance Combo Extends Survival in Extensive-Stage SCLC
4
ctDNA Is Prognostic Regardless of Therapy in Cisplatin-Eligible MIBC
5